Form 4: MAIA Biotechnology Director Acquires Stock Options

A director of MAIA Biotechnology, Inc. acquired 10,225 stock options on December 31, 2024, which vest immediately.

Summary

• Jean-Manasse Theagene, a director at MAIA Biotechnology, Inc., acquired 10,225 stock options on December 31, 2024.
• These options were granted under the company's 2021 Equity Incentive Plan.
• The options have an exercise price of $1.98 and vest immediately upon grant.
• The options are exercisable from the grant date and expire on December 31, 2034.
• The director now beneficially owns 10,225 derivative securities.

Sentiment

Score: 7

Explanation: The transaction is a routine grant of stock options to a director, which is generally viewed as a positive sign of alignment with shareholder interests. The immediate vesting is a positive signal.

Positives

• The immediate vesting of the options suggests confidence in the company's future performance.
• The acquisition of options by a director can be seen as a positive sign of alignment with shareholder interests.

Industry Context

This is a standard transaction for a director of a public company, often used as part of compensation and incentive programs.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in the biotechnology industry.
• The vesting schedule of 100% immediately is not uncommon, especially for smaller grants.
• The 10-year expiration period is also typical for stock options.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, equity incentive plan, director, beneficial ownership, MAIA Biotechnology, derivative securities